LUPIN:NSE:NSE-Lupin Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 2198.25

Change

+14.65 (+0.67)%

Market Cap

USD 998.11B

Volume

0.88M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-0.80 (-0.04%)

USD 4,554.89B
DIVISLAB:NSE Divi's Laboratories Limited

-4.75 (-0.09%)

USD 1,441.57B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+81.40 (+2.40%)

USD 1,154.88B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-102.40 (-1.52%)

USD 1,121.95B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-11.70 (-1.09%)

USD 1,071.49B
MANKIND:NSE Mankind Pharma Ltd

+73.85 (+2.91%)

USD 1,033.59B
AUROPHARMA:NSE Aurobindo Pharma Limited

+7.45 (+0.51%)

USD 851.48B
ALKEM:NSE Alkem Laboratories Limited

+34.85 (+0.57%)

USD 740.60B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

+18.35 (+1.12%)

USD 473.60B
AJANTPHARM:NSE Ajanta Pharma Limited

-26.20 (-0.78%)

USD 418.19B

ETFs Containing LUPIN:NSE

ASIA Matthews International Fu.. 2.21 % 0.00 %

+0.37 (+1.24%)

USD 0.08B
UEVM VictoryShares Emerging Ma.. 0.00 % 0.45 %

+0.74 (+1.24%)

USD 0.19B
DRFE:CA Desjardins RI Emerging Ma.. 0.00 % 0.00 %

+0.04 (+1.24%)

CAD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 67.44% 81% B- 84% B
Dividend Return 0.61% 60% D- 49% F
Total Return 68.05% 81% B- 84% B
Trailing 12 Months  
Capital Gain 90.32% 78% C+ 82% B
Dividend Return 0.69% 56% F 49% F
Total Return 91.01% 77% C+ 82% B
Trailing 5 Years  
Capital Gain 220.21% 43% F 48% F
Dividend Return 4.15% 41% F 29% F
Total Return 224.36% 41% F 47% F
Average Annual (5 Year Horizon)  
Capital Gain 27.24% N/A N/A 39% F
Dividend Return 27.85% N/A N/A 39% F
Total Return 0.61% N/A N/A 49% F
Risk Return Profile  
Volatility (Standard Deviation) 52.14% N/A N/A 47% F
Risk Adjusted Return 53.42% N/A N/A 30% F
Market Capitalization 998.11B 92% A 95% A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector